Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Antonarakis Describes the TAXYNERGY Trial in mCRPC

February 25th 2013

Emmanuel Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the TAXYNERGY trial that is exploring molecular markers of response in men with mCRPC following an early switch in taxane-based treatment.

Docetaxel Dosing Every 2 Weeks May Be Superior to Current Standard Regimen in CRPC

February 25th 2013

Administration of docetaxel every 2 weeks in patients with CRPC was associated with significantly longer time to treatment failure, improved OS, and produced fewer adverse events.

Whole-Blood, 6-Gene Prognostic Signature May Help Personalize Prostate Cancer Treatment

February 18th 2013

Drs William Oh and Yixuan Gong discuss their research involving a whole-blood, 6-gene prognostic signature that has the potential to help personalize prostate cancer treatment.

Dr. Cooperberg on Earlier Treatment With Sipuleucel-T

February 16th 2013

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the earlier administration of treatment with sipuleucel-T for men with prostate cancer.

Dr. Vogelzang Discusses Radium-223 in Prostate Cancer

February 16th 2013

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses an updated analysis of the phase III ALSYMPCA trial that examined radium-223 dichloride in patients who have CRPC with bone metastases.

Dr. Scher on Corticosteroids and Enzalutamide in mCRPC

February 15th 2013

Howard I. Scher, MD, from Memorial Sloan-Kettering Cancer Center, discusses the impact of corticosteroids on outcomes for men with metastatic castration-resistant prostate cancer receiving treatment with enzalutamide.

Dasatinib Combination Fails to Improve Outcomes in mCRPC

February 15th 2013

The addition of dasatinib to standard therapy with docetaxel failed to improve survival and most other clinical endpoints in men with metastatic castration-resistant prostate cancer in the phase III READY trial.

Abiraterone Continues to Show Survival Benefit in Updated Interim Analysis

February 15th 2013

An updated interim analysis of the COU-AA-302 trial upholds the benefits of abiraterone acetate in mildly symptomatic or asymptomatic patients with progressive mCRPC untreated with prior chemotherapy.

Concomitant Corticosteroid Use Dilutes Benefit of Enzalutamide in mCPRC

February 15th 2013

Use of corticosteroids had a negative impact on outcomes with enzalutamide treatment as well as placebo treatment in men with metastatic castrate resistant prostate cancer.

Dr. William Oh Discusses the COU-AA-302 Trial

February 15th 2013

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the third interim analysis of the COU-AA-302 trial that examined abiraterone acetate before chemotherapy in mCRPC.

Dr. Nabid on a Shorter Duration of ADT in Prostate Cancer

February 14th 2013

Abdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer.

Dr. Deepak Kapoor on the Utilization of Prostate Biopsies

February 14th 2013

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the implications of a large study looking at the detection of prostate cancer using prostate biopsies.

Shortened Hormone Therapy Course Feasible for High-Risk Prostate Cancer

February 14th 2013

Shortening the course of androgen blockade therapy from 36 months to 18 months when combined with radiation therapy does not appear to compromise outcomes in patients with high-risk prostate cancer

Aggressive Prostate Cancer Risks Higher in Elderly, African-American Men

February 14th 2013

A large, retrospective study has found that high-risk prostate cancer that can only be detected through PSA testing is more likely to occur among men over the age of 75 and in African Americans.

FDA Gives Radium-223 Priority Review Status

February 13th 2013

Radium Ra 223 Dichloride will be considered as a treatment for patients who have castration-resistant prostate cancer with bone metastases under the FDA's priority review program.

Advanced Prostate Cancer: Therapeutic Sequencing, Outcomes, and Cost Implications

February 7th 2013

There is a dramatic revolution under way in the treatment of advanced-stage prostate cancer, which for many years consisted of systemic chemotherapy that offered only palliation of symptoms and no hope of improved survival.

Dr. James Mohler on Androgen Levels in Prostate Cancer

January 30th 2013

James Mohler, MD, Roswell Park Cancer Institute, explains the progress needed to better understand androgen receptors.

Molecular Switch Identified as Treatment Target in Castration-Resistant Prostate Cancer

January 29th 2013

Researchers have discovered that the oncogenic function of a particular protein in CRPC can cause the cancer to spread without stimulation by male hormones.

Men With High Risk of Skeletal Complications More Likely to Develop Fractures After ADT

January 21st 2013

Men with prostate cancer who had a high baseline risk of skeletal complications developed more fractures and had a higher mortality risk after long-term ADT when compared to men with lower baseline risk factors.

New Oral Androgen Receptor Pathway Agents Are Changing the Way Prostate Cancer Is Treated

January 18th 2013

The treatment of late-stage prostate cancer is shifting; with the approval of two new oral agents there are now more options for men with metastatic prostate cancer then just two years ago.